Drug intelligence / Profile preview

VM-GD

Development stage: Unknown
Lead developer: ViGenCell
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
Administration: Intramuscular

Overview

VM-GD is a plasmid DNA vaccine developed by Helixmith (formerly ViroMed) for the treatment of Graves' disease. The therapeutic consists of a plasmid vector encoding the A-subunit of the human thyroid-stimulating hormone receptor (TSHR). Its mechanism of action involves inducing immune tolerance to TSHR, thereby reducing the production of pathogenic autoantibodies (thyroid-stimulating immunoglobulins) that cause hyperthyroidism. By addressing the underlying autoimmune cause of the disease, VM-GD aims to provide a long-term solution compared to standard antithyroid medications or ablative therapies.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on VM-GD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-GD.

Explore the full profile